medigraphic.com
Anales de Otorrinolaringología Mexicana

2013, Número 3

<< Anterior Siguiente >>

Otorrinolaringología 2013; 58 (3)


Disección electiva del compartimento central en cáncer diferenciado de tiroides. ¿Indicación o recomendación?

Delgado AJLG, Dávalos FMS, del Bosque MJE, García RFM, Medrano ED, Capiz CB

Idioma: Español
Referencias bibliográficas: 36
Paginas: 164-169
Archivo PDF: 395.73 Kb.


RESUMEN

El cáncer diferenciado de tiroides es la neoplasia endocrina maligna más común en el mundo. La enfermedad ganglionar es frecuente, aunque se ha demostrado que no tiene repercusión en la supervivencia. La disección electiva del compartimento central continúa siendo tema de debate y las recomendaciones actuales se basan en la premisa del control locorregional con probable aumento de la supervivencia, aspectos no demostrados en forma concluyente por ausencia de estudios a largo plazo que lo avalen. El aumento teórico en las complicaciones que provoca la disección electiva del compartimento central (lesión a nervios laríngeos e hipocalcemia) ha hecho que algunos autores no la consideren, bajo la premisa, entre otras cosas, del control de la enfermedad mediante ablación con yodo radioactivo. Debido a que no existen estudios que demuestren en forma fehaciente que la disección electiva del compartimento central incida en el pronóstico de los pacientes con cáncer diferenciado de tiroides, en la Unidad de Oncología del Hospital Juárez de México se practicó en pacientes con alto riesgo, según los criterios de AMES (edad, metástasis, la extensión del cáncer primario, el tamaño del tumor).


REFERENCIAS (EN ESTE ARTÍCULO)

  1. National Cancer Institute, Surveillance epidemiology and end results (1975-2007), [en línea] http://seer. cancer.gov/csr/1975_2007/results_merged/sect_26_ thyroid.pdf

  2. Granados-García M, Estrada LE, Apodaca CA. Cáncer diferenciado de la tiroides: aspectos generales. Cancerología 2009;4:65-71.

  3. Cady B, Rossi R. An expanded view of risk group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-953.

  4. Ort S, Goldenberg D. Management of regional metastases in well-differentiated thyroid cancer. Otolaryngol Clin N Am 2008;41:1207-1218.

  5. Hughes CJ, Shaha AR, Shah JP, Loree TR. Impact of lymph node metastasis in differentiated carcinoma of the thyroid: a matched-pair analysis. Head Neck 1996;18:127-132.

  6. Sato N, Oyamatsu M, Koyama Y, Emura I, et al. Do the level of nodal disease according to the TNM classification and the number of involved cervical nodes reflect prognosis in patients with differentiated carcinoma of the thyroid gland? J Surg Oncol 1998;69:151-155.

  7. Shah MD, Hall FT, Eski EJ, Witterick IJ, et al. Clinical course of thyroid carcinoma after neck dissection. Laryngoscope 2003;113:2102-2107.

  8. Carling T, Long WD, Udelsman R. Controversy surrounding the role for routine central lymph node dissection for differentiated thyroid cancer. Curr Opin Oncol 2010;22:30-34.

  9. Miller BS, Doherty GM. An examination of recently revised differentiated thyroid cancer guidelines. Curr Opin Oncol 2011;23:1-6.

  10. Choi SJ, Kim TY, Lee JC, Shong YK, et al. Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? Clin Exp Otolaryngol 2008;1:41-45.

  11. Orloff LA, Kuppersmith RB. American thyroid association’s central neck dissection terminology and classification for thyroid cancer consensus statement. Otolaryngol Head Neck Surg 2010;142:4-5.

  12. Fritze D, Doherty GM. Surgical management of cervical limph nodes in differentiated thyroid cancer. Otolaringol Clin N Am 2010;43:285-300.

  13. Hughes DT, Doherty GM. Central neck dissection for papillary thyroid cancer. Cancer Control 2011;18:83- 88. [On line] Disponible en: http://www.moffitt.org/ CCJRoot/v18n2/pdf/83.pdf

  14. White ML, Gauger PG, Doherty GM. Central lymph node dissection in differentiated thyroid cancer. World J Surg 2007;31:895-904.

  15. Pereira JA, Jimeno J, Miquel J, Iglesias M, Munné A. Nodal yield, morbidity, and recurrence after central neck dissection for papillary thyroid carcinoma. Surg 2005;138:1095-1101.

  16. Chung YS, Suh YJ. Is central lymph node dissection mandatory in 2 cm or less sized papillary thyroid cancer? J Korean Surg Soc 2010;79:332-339.

  17. Rosenbaum MA, McHenry CR. Central neck dissection for papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2009;135:1092-1097.

  18. Sywak M, Cornford L, Roach P, Stalberg P, et al. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. Surgery 2006;140:1000-1007.

  19. Low TH, Delbridge L, Sidhu S, Learoyd D, et al. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Ann Surg Oncol 2008;15:2827- 2832.

  20. Hughes DT, White ML, Miller BS. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery 2010;148:1100-1107.

  21. Tisell LE, Nilsson B, Molne J, Hansson G, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg 1996;20:854-859.

  22. Costa S, Giugliano G, Santoro L, de Carvalho AY, et al. Role of prophylactic central neck dissection in cN0 papillary thyroid cancer. Acta Otorhinolaryngol Ital 2009;29:61-69.

  23. Shindo M, Wu JC, Park EE, Tanzella F. The importance of central compartment elective lymph node excision in the staging and treatment of papillary thyroid cancer. Arch Otolaryngol Head Neck Surg 2006;132:650-654.

  24. Lee YS, Kim SW, Kim SW, Kim SK, et al. Extent of routine central lymph node dissection with small papillary thyroid carcinoma. World J Surg 2007;31:1954-1959.

  25. Fu JY, Wu Y, Wang ZY, Sun TQ, Xiang J. Clinical and pathological analysis of central compartment dissection in patients with papillary thyroid cancer with negative clinical lymph node metastasis. Chin J Surg 2007;45:470-472.

  26. Henry JF, Gramatica L, Denizot A, Kvachenyuk A, Puccini M. Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinomas. Langenbecks Arch Surg 1998;383:167-169.

  27. Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope 2009;119:1135-1139.

  28. Khafif A, Medina JE. Management of the N0 neck in thyroid malignancy. Curr Opin Otolaryngol Head Neck Surg 2001;9:85-89.

  29. Simon D, Goretzki PE, Witte J. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;20:860-866.

  30. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 2004;136:1183-1191.

  31. Chao TC, Lin JD, Chen MF. Insular carcinoma: infrequent subtype of thyroid cancer with aggressive clinical course. World J Surg 2004;28:393-396.

  32. Patel NK, Shaha AR. Poorly differentiated and anaplastic thyroid cancer. Cancer Control 2006;13:119-128. [On line] Disponible en: http://www.moffitt.org/CCJRoot/ v13n2/pdf/119.pdf

  33. Justin EP, Seabold JE, Robinson RA, Walker WP, et al. Insular carcinoma: A distinct thyroid carcinoma with associated Iodine-131 localization. J Nucl Med 1991;32:1358-1363.

  34. Goretzki PE, Simon D, Frilling A, Witte J, et al. Surgical reintervention for differentiated thyroid cancer. Br J Surg 1993;80:1009-1012.

  35. Kim MK, Mandel SH, Baloch Z, LiVolsvi VA, et al. Morbidity following central compartment reoperation for recurrent or persistent thyroid cancer. Arch Otolaryngol Head Neck Surg 2004;130:1214-1216.

  36. Zuñiga S, Sanabria A. Prophylactic central neck dissection in stage N0 papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2009;135:1087-1091.




2020     |     www.medigraphic.com